EPISODE · Dec 7, 2022 · 10 MIN
Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns
from PeerVoice Clinical Pharmacology Video · host PeerVoice
Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns
Embed this episode
What this episode covers
Visit https://www.peervoice.com/MCB860 to view the entire programme with slides. After completing “Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns”, participants will be able to: Discuss real-world evidence with BTK inhibitors for chronic lymphocytic leukemia (CLL), focusing on safety considerations; and Propose strategies to manage safety concerns and maximize benefits from BTK inhibitors therapy in patients with CLL.
Ready to play
Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns
No transcript for this episode yet
Similar Episodes
No similar episodes found.